By- Dr.
Santosh Patil
Gastroenterology
Peptic ulcer ->
·
IstMK -
H. Pylori
NSAIDs
· 2nd M1c-
· Mc complication ofPUD ->
Bleeding
peptic ulcer
R.
H. Pyloxi
·
Recommended regimen:Bismuth
containing
quadruple regimen
-Clarithromycin
Drug
posted X
·
resistence
Metronidazole
Components <
BMT->
Tetracycline
Omeprazole)inMetronidazole
subsalicylate
·Duration of R- 10-14 days
Liver:
·
MICK Cirrhosis (CLD -> NAFLD
foracute lives failure E
hepatitis.
India:Viral
World:Drugs -
MI Paraceta
- mol
Question ·2nd Mick for acule
Type question here
-
Liver
In
failure) 18s
India
⑰k
Defn
↳
Acute lives
ATT
·
failure
Developmentof hepatic encephalopathy
onset of
Ein dys/wke of
AASLD.
Acc. to
jaundice.
-
-
ACC INASL
-> ↳4
s,
disorder:
· Autoimmune hepatobiliary
Autoimmune hepatitis
Lupoid
1)
= -
patitis
ass. SLE
-
Anti-LKM1 antibody -
R ->
Oral corticosteroids
1st line agents -
ii) Primary Biliary Cholangitis:
Prim. biliary
cirrhosis
~
Autoimmune disorder
affecting small & medium
bile ducts.
sized
,oproo
Antimiton
-ANTB dria
Intrahepatic cholestasis
Fatigue
-
Mc symptom
~
2nd Mk symptom ->
Itching/pruvitis
choice:Ursodeoxycholic
Drug of
~
acid.
-and line
Obeticholic
:
agent
acid
(add on) -
Farsenoid
Mech. of action:
X R
-
iii) Primaxy Sclerosin
I agonist
cholangitis:
·PY
·
small/medium ↳
Autoimmune disordel
tra
affecting
-
ANTB
Al ~
CF a large
-
Entire
bile ducts hepalic
biliarTree Cholestasis
P
· On
imaging? dilated intrahepatic
radicles.
biliary
association
strong citis.
ulcerative
R Doc- Ursodeoxycholic acid.
Respiratory System:
·
Asthma-
10c ->
Spirometry IPFT
Y
IOC in the
PEFR
absence of orCII for
spirometry
Diagnostic criteria:
FEV1
is - bsed
ratio
10.7
ii) FEX, IFV
<0:7
iii) Bronchodilator
revessibility test
⑭test-
to
Done
If
-
FEV, increases
diff blu
by > 12% or
Asthma
>200m
by
ED
S/0 astuma.
COPD
Asthma
↓sed ↓, sed
FEX,
<0.7
<0.7
FEX, II
No use in FEN,
FEV1 ↑ses by
I
BDR if
increase,
>127 or
* 12-1
DLCO
Normal/Ased. ↓sed
·
Phenotypical classification:
Non Type R
Type 2
- ·
Th1 GT1z
·
The cell mediated
inflammation
Eosinophils Neutrophils
Eftes y
·
11
111
·
Inflammatory-
3 125
111t
cytokines
IgE
- 183
Hing
targe
·
Dupilimumab
-
Anti-ILR
Reslizumab Antil 15
·
Bensalizumab-115R
Anti-
Mepolimumab
·
-
Anti-IL5
Omalizumab
·
Anti-IGE
-
COPD: Persistent
- -
disorder
· Chronic obstructive lung
small, medium
Enlarge
affecting Cirwar
I also Lung parenchyma
·
Mick -
smoke
smoking
for
Mick
cops in non-smoking
q) Burning of
biomass feed
<Chora)
Asist
·
FEX 1
used
PFT:
FEV, /FVC 50.7
DDB test) FEx, 4x [12%
DLCO-lised
CXR-
i) Flattened diaphragm
ii) Widened rib spaces
iii) Tubular
heart
DS -
Berlin Criteria
Diagnostic criteria
-
Hypoxia ->
-
ak,
rato (300
PaOzIFiO2
x > 400
200
Mild
⑰00
not
was
.
be
alveolar moderate
opacities
⑩
I
severe
·
Cardiac r
2D Echo 1
=
cause
ruled
orinvasive
out
monitoring
vell
Temporal
·
onset) <7days.
bIn trigger & ARDS
Classification of causes for ARDS
---
C
Extrinsic
Intrinsic
-
M/ sepsis
MIC Pneumonia
Management:
choice:Mechanical Ventilation
12 of
Ventilatorysettings
recommended:
·
Ty-low tidal vol=GmL/kg body not.
·
PEEP- High PEEP
strategy
[30cmU2O
·Plateau pressure
· Prone position ventil for ARDS
moderate
ARDS
·
ECMO -for severe
in male,
MK -
11DS smokers
11D Idiopathic
of
->
1 type chronic
pulmonary fibrosis
related
smoking Desquamative
·
ILDS interstitial
(DIP)
Pneumonia
bronchiolitis
"Respiratory
associated ILD
(RB-11D)
it) ishcodeater
·
Most common
genelic abnormality
in pts =
CIPE)
·
Mostcommon ILD in
Idiopathic
->
non-smoking females non-specific
interstitial
pneumonia
CIdiopathic
NS1P)
IPF NS1P
40-50 yrs
> 60
ce yrs
Males
Females
Gender
Strong Occurs in
Smokin
g "isk non-smokers
Usual Interstitial NSIP
HRCT
Pneumonia pattern
CUIPY pattern
Ground glass
·
Honey-comb apacities
appearance
Prognosis Poor Good
Ansculta
findings
in IOF ↳ fine, end
crepitation
inspiratory
"Velcro like"
&
of ICD
[Nintedanib I
Pirfenidone Anti
1st line
IPF -
agents
fibrotic
agents
3
and line
Immunosuppressants
agents
Definitive Lung transplantation
NSIP->
1stline
agents steroids
2nd
agents ↳
line
Immuno
suppressants.
isofsmoking
y
·
smoking
IQuit
related ILDS
(D1P (RB-11-D) steroids
·Which is mimicks ARDS: Diffuse alvelar
hemorrhage (DAH)
·
Sarcoidosis
inflamma
-
Multisystems autoimmune
toty
disorder.
~
MIC
affected system:Respiratory system.
Hilar lymphadeno
E
Granulomas path
t
Non-caseating Parenchymal involvement
>
Erythema
~and modosum
M1c affected -> Skin
organ Lupus
pernio
~
MIC CNS
-> th neuve
palsy
manifesto
-
MIC venal
- Interstitial
manifests nephritis.
Staying of
Savcoidosis:
Scadding
staging
Lagnosis:
i) S. ACE I sed
ii) Rest.
Negative CBNAAT or IGRA
iii)
Biopsy slo non-ascating
granulomas
Ov
Typical imaging
finding
aging modalityof 10
· per t
② Gallium scan
is"Panda sign"
ii)" Lambda sign"
X
R -
DOC -
Corticosteroids
2
ine 4 Immunosuppressants. -
Neurology
2nd MIC
-
einer's disease ->
Parkinson's
dis
disorder
·
Mc neurodegenerative
Gemelic:
i) Presenilin-1 muth
ii) ApoE variants
(Apo E (En)
iii) Down's syndrome
>
Earliest
·
sile to Entorhinal
get
affected contex
itsn
pot
rise Earliest loss
symptom Memory
->
is
Messed a e
>
ent memory
>Renole
memory
e -
pP ·
Metal
I
toxicity
Y sed AD risk b Aluminium
Clinical
ggnosis
-
--
for Dementia
Reversible Causes
Biz
Niacin
I deficience
Hypothyroidism
Normal pressure
hydrocephalus
CNS
infections
NAME OF TEST ON APP DATE
FMGE TEST- 1 16.7.23
FMGE TEST- 2 23.7.23
FMGE TEST- 3 25.7.23
FMGE TEST- 4 26.7.23
FMGE TEST- 5 27.7.23
